Klaria Pharma Holding Year-End Report

Additions to the management team and structural changes to prepare for an increased focus on clinical development and out-licensing

FOURTH QUARTER (OCTOBER–DECEMBER)

∞ Net sales amounted to 0.2 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 9.7 MSEK (7.2 MSEK)

∞ Profit after tax amounted to -5.3 MSEK (-8.1 MSEK)

∞ Earnings per share for the quarter amounted to -0.17 SEK (-0.26 SEK)

∞ Cash flow from operating activities amounted to -5.7 MSEK (-2.9 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 2.9 MSEK (8,0 MSEK)

∞ Shareholder’s equity per December 31, 2019 amounted to 82.1 MSEK (94.7 MSEK)

THE PERIOD JANUARY–DECEMBER

∞ Net sales amounted to 4.2 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 24.2 MSEK (22.6 MSEK)

∞ Profit after tax amounted to -22.5 MSEK (-27.3 MSEK)

∞ Earnings per share for the quarter amounted to -0.73 SEK (-0.89 SEK)

∞ Cash flow from operating activities amounted to -14.8 MSEK (-9.1 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 2.9 MSEK (8.0 MSEK)

∞ Shareholder’s equity per December 31, 2019 amounted to 82.1 MSEK (94.7 MSEK)